SignalRx Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.signalrx.com
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- SignalRX Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03059147
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
© Copyright 2024. All Rights Reserved by MedPath